Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Ef
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate) | Business Wire
Idarucizumab for Dabigatran Reversal – The Bottom Line
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Idarucizumab (PRAXBIND) | STROKE MANUAL
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols - ScienceDirect
Idarucizumab, the Sequel – Emergency Medicine Literature of Note
Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant - Labiotech.eu
Idarucizumab for Reversal of Dabigatran – Core EM
Clinical Evidence | Praxbind® (idarucizumab)
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
Clinical Evidence | Praxbind® (idarucizumab)
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
Praxbind Full Prescribing Information, Dosage & Side Effects | MIMS Thailand
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment | Journal of the American College of Cardiology
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis - MPR
Frontiers | Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting
Idarucizumab: Plenty of optimism, not enough science - First10EM
Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre - Wheeler - 2019 - Internal Medicine Journal - Wiley Online Library
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination - Stephan Glund, Guanfa Gan, Viktoria Moschetti, Paul Reilly, Markus Honickel, Oliver Grottke, Joanne Van Ryn,
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study - Yasaka - 2017 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library
